XBIO
Xenetic Biosciences Inc
$
2.770
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.900
Open
2.900
VWAP
2.85
Vol
10.19K
Mkt Cap
4.27M
Low
2.770
Amount
29.03K
EV/EBITDA(TTM)
--
Total Shares
1.54M
EV
-890.15K
EV/OCF(TTM)
--
P/S(TTM)
1.65
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
769.12K
+18.43%
--
--
718.73K
+17.03%
--
--
639.16K
-12.3%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Xenetic Biosciences, Inc. (XBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.65%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-10.65%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Xenetic Biosciences Inc (XBIO.O) is -0.91, compared to its 5-year average forward P/E of -2.93. For a more detailed relative valuation and DCF analysis to assess Xenetic Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.93
Current PE
-0.91
Overvalued PE
-1.23
Undervalued PE
-4.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.08
Current EV/EBITDA
0.11
Overvalued EV/EBITDA
1.13
Undervalued EV/EBITDA
-0.98
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
9.06
Current PS
1.63
Overvalued PS
18.43
Undervalued PS
-0.30
Financials
Annual
Quarterly
FY2025Q1
YoY :
+16.14%
593.26K
Total Revenue
FY2025Q1
YoY :
-25.70%
-942.41K
Operating Profit
FY2025Q1
YoY :
-24.43%
-903.14K
Net Income after Tax
FY2025Q1
YoY :
-24.36%
-0.59
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-34.93%
-152.23
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
XBIO News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
09:11:50
Xenetic says PeriNess enters clinical study agreement for DNase Platform
2025-07-23 (ET)
2025-07-23
08:43:37
Xenetic expands collaboration with The Scripps Research Institute
2025-07-08 (ET)
2025-07-08
09:10:45
Xenetic says PeriNess reports Bnei Zion Medical Center commences patient dosing
Sign Up For More Events
Sign Up For More Events
News
9.0
03-13Business InsiderXenetic presents preclinical data on DNase I with CAR T cells in murine model
4.0
2024-11-22BenzingaHC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences
9.5
2024-11-12NASDAQ.COMProgyny (PGNY) Tops Q3 Earnings Estimates
Sign Up For More News
People Also Watch
IMG
CIMG Inc
0.350
USD
-18.03%
EVOK
Evoke Pharma Inc
5.440
USD
+2.06%
UBXG
U-BX Technology Ltd
2.829
USD
+0.68%
BLBX
Blackboxstocks Inc
6.540
USD
-2.24%
ONFO
Onfolio Holdings Inc
1.070
USD
-2.02%
CREG
Smart Powerr Corp
1.410
USD
-12.96%
GRI
GRI Bio Inc
1.260
USD
+0.80%
PLRZ
Polyrizon Ltd
1.100
USD
-5.17%
CMND
Clearmind Medicine Inc
0.987
USD
-3.24%
XHG
XChange TEC.INC
1.207
USD
-1.07%
FAQ
What is Xenetic Biosciences Inc (XBIO) stock price today?
The current price of XBIO is 2.77 USD — it has decreased -6.73 % in the last trading day.
What is Xenetic Biosciences Inc (XBIO)'s business?
What is the price predicton of XBIO Stock?
What is Xenetic Biosciences Inc (XBIO)'s revenue for the last quarter?
What is Xenetic Biosciences Inc (XBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Xenetic Biosciences Inc (XBIO)'s fundamentals?
How many employees does Xenetic Biosciences Inc (XBIO). have?